VNA
SIOX

Valley National Advisers’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Valley National Advisers’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-250
Closed -$2K – 839
2019
Q3 		$2K Buy
+250
New +$1.72K ﹤0.01% 693

Other funds holding SIOX

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EWM
Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Valley National Advisers's SIOX Position: Q4 2019 in Review

Valley National Advisers sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2019, closing a stake of 250 shares — an estimated $2K sold.

Valley National Advisers first reported a position in SIOX in Q3 2019 and held it in 1 quarter. The position peaked at $2K in Q3 2019. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2019.

  • Valley National Advisers reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Valley National Advisers sold 250 Sio Gene Therapies Inc. Common Stock shares in Q4 2019, an estimated $2K.
  • Valley National Advisers first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Valley National Advisers's Sio Gene Therapies Inc. Common Stock position peaked at $2K in Q3 2019.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2019.

Based on Valley National Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.